Understanding the Clinical, Regulatory, and Research Challenges Shaping Women’s Hormone Care
Women’s hormone therapy has been influenced by decades of misinformation; such as research gaps, underrepresentation, unequal research, and evolving regulatory policies that continue to affect patient care today. In this thought-provoking webinar, Angela DeRosa, DO, MBA, CPE, Medical Director at Belmar Pharma Solutions, examines how gender bias has shaped the diagnosis and treatment of women’s hormonal health and why healthcare providers must advocate for evidence-based, individualized care.
Drawing on her extensive clinical experience and leadership in women’s health, Dr. DeRosa explores the historical, scientific, and regulatory factors that continue to influence access to bioidentical hormone replacement therapy (BHRT) and personalized therapy options for women.
What You’ll Learn
Dr. DeRosa reviews the historical origins of gender bias in medicine, including disparities in clinical research, pharmaceutical development, and representation of women in hormone therapy studies. She explains how these long-standing issues have contributed to limited FDA-approved hormone therapy options for women, particularly testosterone therapy, while highlighting the importance of interpreting scientific evidence within the broader context of women’s health. The webinar also examines the National Academies of Sciences, Engineering, and Medicine (NASEM) report on compounded bioidentical hormone therapy, and discusses its potential implications for healthcare providers and patient access to personalized medicine.
Advocating for Personalized Women’s Hormone Care
Throughout the presentation, Dr. DeRosa encourages providers to critically evaluate the evidence behind clinical guidelines, recognize potential conflicts of interest in medical research, and remain focused on individualized patient care. She discusses the important role compounded bioidentical hormone therapies play in addressing treatment gaps that cannot always be met by commercially available products, while emphasizing the need to preserve clinical judgment and expand access to personalized hormone therapy for women.
Whether you currently provide hormone therapy or are considering adding women’s hormonal health services to your practice, this webinar offers valuable perspective on the evolving landscape of BHRT and the importance of ensuring women have access to safe, evidence-informed, individualized care.
This webinar is intended for providers seeking a broader understanding of women’s HRT compounding options and the clinical considerations associated with personalized hormone therapy.
If you are a provider and would like to watch the webinar, please fill out the form below.
This webinar is intended for prescribers. If you are a prescriber and would like to watch the webinar, please fill out the form below. You will be re-directed to the recording after successful completion of form.
